Navigation Links
Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program
Date:1/20/2009

SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced that it will focus resources on the development of its natriuretic peptide franchise, including CD-NP which is in Phase II development for acute heart failure, and CU-NP which is a pre-clinical compound. Nile will suspend the further development of 2NTX-99 and return license rights for the compound to Dr. Cesare Casagrande.

"We are disappointed that we are unable to continue to pursue the development of 2NTX-99," stated Peter Strumph, Chief Executive Officer of Nile. "We have decided to terminate this program in order to focus our resources on our core natriuretic peptide program, which is showing great promise as a potential treatment for cardiovascular and renal disease."

Results from two completed Phase I studies and the ongoing open-label Phase IIa study support advancing the CD-NP development program into a Phase IIb clinical study. Current development plans include initiating a 30 patient placebo-controlled clinical study of acute heart failure patients with renal impairment. This study is designed to assess safety and efficacy of early administration of CD-NP in this patient population and may provide additional evidence to support the hypothesis that CD-NP enhances renal function. Such results would build upon the recently completed Phase Ib study in which CD-NP demonstrated diuretic effects comparable to furosemide and produced statistically significant changes on biomarkers consistent with enhanced renal function.

"Another study showing that CD-NP enhances renal function will go a long way towards establishing that CD-NP has differentiated and favorable renal properties relative to current and development treatments for acute heart failure," commented Peter Strumph. "In addition, this study, which ca
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
2. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
3. Dr Stephan Rietiker Joins BioCeramic Therapeutics
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
6. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
7. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
8. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
9. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
10. Horizon Therapeutics Announces Senior Management Appointments
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... Dr. Mate Hidvegi, inventor of Avem...ss release issued on November 17 by Biropharma Kft...lse and self-serving statements about its U.S. com...tated from his office in Budapest, Hungary: ,,...s not apply to AveULTRA, www.aveultra.com , is ...
(Date:11/19/2009)...PRNewswire-FirstCall/ -- Spherix Incorporated (Nas...abetes therapy, and a provider of technical and re...biotechnology and pharmaceutical companies, today ...of Shareholders. ,, At the meeting, shareholder... the following members to the Board of Directors: ...
(Date:11/19/2009)...swire/ - Aegera Therapeutics Inc. announced today ...ase 2B study of AEG35156, a targeted antisense the...ology indications. ,, The study, entitled "An O... Inhibitor of Apoptosis (XIAP) Antisense AEG35156 ... Idarubicin in AML Following Failure of a Single S...
(Date:11/19/2009)...s honored by latest award for revolutionary hearin...B) November 16, 2009 -- Popular Science Magazine h... aid from InSound Medical a winner of its coveted ...ory.    Chosen from thousands ...he hearing canal for up to four months while provi...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...d its,plans to seek a listing of at least two of i...e Middle East. In a statement released in Abuja,to...al Oji said that "this,was part of a comprehensive...ng over the next two years. Chrome recently signed...oleo Brasileiro S/A, Dedini Industries,de Base S/A...
...otes Competitiveness with 2... Five Pennsylvania,organizations will be honored ...Keystone Alliance for Performance Excellence (KAPE...-7, 2007 in Harrisburg, PA. The high-performing P...re: -- Advent Design Corporation, Bristol, PA --...
...personal reasons -, FREMONT, Calif., Aug. 20 PDL...unced that a three-month internal,investigation of... McDade,found no credible evidence of improper per...e to corroborate the various allegations,investiga...wing the,investigation and due to the personal tol...
Other Biology Technology:Chrome Group to Seek Listing for Some of its Subsidiaries 2Chrome Group to Seek Listing for Some of its Subsidiaries 3Chrome Group to Seek Listing for Some of its Subsidiaries 4KAPE to Honor High-Performing Pennsylvania Organizations 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 4
(Date:11/19/2009)...fungus for food, have many remarkable qualities. ...armers, like their human counterparts, depend on n.... The finding, reported this week (Nov. 20) in the... symbiosis between ants and bacteria and provides ...inate the American tropics and subtropics. , Wha...
(Date:11/19/2009)...ti-institutional effort co-led by three Cold Sprin...oday in publication of a landmark series of papers...ed detail the DNA sequence of maize ( Zea mays ). ...American consumers, is one of the world,s most imp...rop grown in the United States, representing $47 b...
(Date:11/19/2009)...ble farming, initially adopted to preserve soil qu... in maintaining a healthy climate, according to re...and Los Alamos national laboratories. , ORNL and... of the earth,s soils to sequester carbon, with es... greatly reduce U.S. carbon emissions by as much a...
Breaking Biology News(10 mins):Like humans, ants use bacteria to make their gardens grow 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4ORNL, Los Alamos pioneer new approach to assist scientists, farmers 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 3Viagra Trial for Sickle Cell Lung Problems Halted 52974 1Viagra Trial for Sickle Cell Lung Problems Halted 52974 2Viagra Trial for Sickle Cell Lung Problems Halted 52974 3Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4 13235 1Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4 13235 2Updated CDC Travel Health Book Released 52968 1Updated CDC Travel Health Book Released 52968 2Updated CDC Travel Health Book Released 52968 3
...on: , , The evolution of hydroecology/ecohydrolog...ctions, dynamics and linkages , Methological appro...needs , , The book considers a range of organisms...-term perspective on contemporary and palaeosystem... respect to environmental and water resource manag...
...urfaces are teeming with microbial life, yet the i...stems to fend off any intruding microorganisms the...hed in the online open access journal, BMC Biology...mmune system. , Study authors Dalial Freitak, Dav...itute for Chemical Ecology in Jena, Germany along ...
...Jiri Mestecky, M.D., Ph.D, a University of Alabama... medicine, has been awarded the 2007 Czech Mind pr...c honor in the Czech Republic, and recipients ofte...es. , Mestecky came to UAB in 1967 and continues ...ent of the gut, mouth and mucosal membranes. , Hi...
Other Biology News:Insect gut detects unhealthy meal 2UAB microbiologist wins top Czech science honor 2
McCown's Woody Plant Basal Salt Mixture from Sigma-Aldrich
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
Nutrient Mixture F-12 Ham, Coon's Modification (Ham's F-12 Coon's) from Sigma-Aldrich
...lanced salt solution. It is routinely used as an a... storage of whole blood at refrigerator temperatur...l volume of blood is collected into a container of...he solution is placed in a refrigerator at 2-8 C f...
Biology Products: